Related Experiment Video

Updated: Jun 25, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

[Wilson's disease in paediatric age: diagnosis and treatment. Recent advances]

Emilio Palumbo1

  • 1Reparto di Pediatria, Ospedale, Sondrio. emipalu2003@yahoo.it

Recenti Progressi in Medicina
|February 13, 2009
PubMed

Insights

Wilson disease, a genetic disorder affecting copper excretion due to ATP7B gene mutations, causes copper buildup in organs. Recent advancements focus on improving diagnosis and treatment strategies for affected children.

Area of Science:

  • Genetics
  • Hepatology
  • Neurology

Background:

  • Wilson disease is an inherited disorder characterized by impaired copper excretion, stemming from mutations in the ATP7B gene.
  • This genetic defect leads to excessive copper accumulation, primarily affecting the liver and brain.
  • Clinical presentations are diverse, encompassing hepatic, neurological, psychiatric, and ophthalmological symptoms.

Discussion:

  • This review highlights recent breakthroughs in diagnosing Wilson disease in pediatric patients.
  • It examines novel therapeutic approaches and their efficacy in managing copper overload.
  • The article emphasizes the importance of early detection and intervention for better patient outcomes.

Key Insights:

  • Genetic mutations in ATP7B are the primary cause of Wilson disease.
  • Copper accumulation significantly impacts multiple organ systems, leading to varied clinical manifestations.
  • Advances in diagnostic tools and treatment protocols are crucial for managing pediatric Wilson disease.

Outlook:

  • Future research directions include developing more precise diagnostic methods and personalized treatment plans.
  • Continued investigation into the long-term effects of novel therapies is essential.
  • Improving global access to diagnosis and treatment will be key to reducing the burden of Wilson disease.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...